Drug Trial Radar · NCT07234032
An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
344
Planned (sponsor's estimate)
Start
Jul 20, 2026
Primary completion
Jan 22, 2031
Study completion Jan 22, 2031
Sponsor
- Lead sponsor
- Insmed IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PH-ILD from Study INS1009-311 (NCT07179380).
Conditions
- Pulmonary Hypertension
- Interstitial Lung Disease
Interventions
Treprostinil Palmitil Inhalation PowderDrug
Oral inhalation using a capsule-based dry powder.
PlaceboDrug
Oral inhalation in initial double-dummy titration period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 108 weeks
Locations
12 sites in 8 countries. Site status is shown where the registry gives one.
USA006
Naples, Florida · Recruiting
USA003
Bend, Oregon · Recruiting
CZE001
Prague, Czechia · Recruiting
FRA003
Le Kremlin-Bicêtre, France · Recruiting
GEO003
Tbilisi, Georgia · Recruiting
DEU010
Gauting, Germany · Recruiting
DEU006
München, Germany · Recruiting
JPN007
Yokohama, Japan · Recruiting
JPN004
Narita, Chiba, Japan · Recruiting
KOR001
Seoul, South Korea · Recruiting
ESP006
Madrid, Spain · Recruiting
ESP003
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.